Position in CELC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$32,176,522
+$549,467 QoQ
Shares Held
281,904
-11.1% QoQ
Ownership
0.578%
of shares outstanding
% of Portfolio
5.83%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Saturn V Capital Management LP holds $491,754,102 across 20 Biotechnology names. CELC ranks #6 (6.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALMS |
Alumis Inc.
|
3,202,075 | $70,541,712 | |
| 2 | ABVX |
Abivax S.A.
|
542,696 | $60,429,199 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
824,532 | $47,913,554 | |
| 4 | PHVS |
Pharvaris N.V.
|
1,201,402 | $33,939,606 | |
| 5 | IMMX |
Immix Biopharma, Inc.
|
3,693,585 | $33,648,559 | |
| 6 | CELC |
Celcuity Inc.
This page
|
281,904 | $32,176,522 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
162,961 | $30,807,777 | |
| 8 | IRON |
Disc Medicine, Inc.
|
449,926 | $28,768,268 |
All Filings in CELC
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $32,176,522 | 281,904 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $31,627,055 | 317,095 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $23,407,103 | 473,828 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $15,826,692 | 1,185,520 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $11,057,074 | 1,093,677 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $13,924,919 | 1,063,783 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $14,109,854 | 946,335 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $12,464,213 | 760,941 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||